JELMYTO Drug Patent Profile

Which patents cover Jelmyto, and what generic alternatives are available?

Jelmyto is a drug marketed by Urogen Pharma and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has nine patent family members in six countries.

The generic ingredient in JELMYTO is mitomycin. There are seven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the mitomycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jelmyto

A generic version of JELMYTO was approved as mitomycin by HIKMA on April 19^th, 1995.

Summary for JELMYTO

International Patents:	9
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JELMYTO

Paragraph IV (Patent) Challenges for JELMYTO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JELMYTO	Powder for Injection	mitomycin	40 mg/vial	211728	1	2023-12-28

US Patents and Regulatory Information for JELMYTO

JELMYTO is protected by three US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Urogen Pharma	JELMYTO	mitomycin	POWDER;PYELOCALYCEAL	211728-001	Apr 15, 2020		RX	Yes	Yes	12,268,745
Urogen Pharma	JELMYTO	mitomycin	POWDER;PYELOCALYCEAL	211728-001	Apr 15, 2020		RX	Yes	Yes
Urogen Pharma	JELMYTO	mitomycin	POWDER;PYELOCALYCEAL	211728-001	Apr 15, 2020		RX	Yes	Yes	9,950,069		Y
Urogen Pharma	JELMYTO	mitomycin	POWDER;PYELOCALYCEAL	211728-001	Apr 15, 2020		RX	Yes	Yes	9,040,074		Y

International Patents for JELMYTO

See the table below for patents covering JELMYTO around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2011089604
European Patent Office	2525777	MATÉRIEL ET PROCÉDÉ DE TRAITEMENT DE CAVITÉS INTERNES (MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES)
Germany	212011100034
Israel	221040	חומר ושיטה לטיפול בחללי גוף פנימיים (Material and method for treating internal cavities)
Israel	230530	חומרים ושיטה לטיפול בחללים של הגוף (Materials and method for treating internal body cavities)
World Intellectual Property Organization (WIPO)	2013011504

Investment and Fundamentals Analysis of JELMYTO (mitomycin for injection)

Last updated: February 20, 2026

What is the current market position of JELMYTO?

JELMYTO (mitomycin for injection) is a prescription medication approved by the FDA in April 2021 for the treatment of low-grade upper urinary tract urothelial cancer (LG UTUC), a rare bladder cancer subtype. Developed by UroGen Pharma, JELMYTO is a local, controlled-release formulation of mitomycin designed for outpatient instillation therapy.

As a first-in-class product, JELMYTO addresses a high unmet need within niche oncology, with a specific focus on patients ineligible or unwilling to undergo surgery. Its novel delivery mechanism distinguishes it from systemic chemotherapies, positioning it as a specialized asset within the uro-oncology market.

What are the sales and revenue prospects?

Marketed as a specialty drug with limited but focused indications, JELMYTO’s commercial success depends on factors including:

• Patient population size
• Eligibility and adoption rates
• Physician prescribing behavior
• Competitive landscape

Estimates suggest approximately 2,500-3,000 new cases of LG UTUC are diagnosed annually in the U.S. (NA). The treatment landscape is limited, with standard options involving invasive procedures such as nephroureterectomy.

Initial sales in 2022 reflect modest uptake, driven by physician education and insurance coverage. Analysts project a compounded annual growth rate (CAGR) of approximately 10-15% over the next five years, reaching peak sales between $100 million and $150 million by 2027, assuming favorable adoption and market expansion.

What are the key operational and regulatory factors?

JELMYTO's regulatory pathway involved accelerated review, leveraging its designation as a rare disease drug. Key points include:

• FDA approval in April 2021 based on pivotal Phase 3 trial data showing significant remission rates.
• Post-marketing commitments include further studies confirming long-term efficacy and safety.
• Pricing: The drug is priced at approximately $13,000 per bladder instillation, with a typical course involving multiple administrations per patient.
• Insurance coverage: Critical for commercial success. Third-party payers have shown willingness to reimburse for JELMYTO due to its clinical benefits over surgical options.

Regulatory risk remains limited given FDA approval but includes potential delays or restrictions based on post-approval data requirements.

What are the drivers and risks of growth?

Drivers:

• Unmet clinical need for less invasive treatment options.
• Market expansion into non-U.S. markets with similar indications.
• Physician education enhancing prescribing rates.
• Insurance reimbursement improving patient access.

Risks:

• Limited patient population constrains revenue potential.
• Pricing pressures from payers or health systems.
• Competitive developments—new therapies or improved surgical techniques—could reduce market size.
• Long-term safety data is pending and could impact perceived value.

What is the competitive landscape?

JELMYTO's primary competitors include systemic chemotherapy agents and emerging targeted therapies. Currently, no direct branded alternatives exist for LG UTUC, but surgical interventions and systemic chemotherapy are standard.

Potential threats include:

• Emerging therapies with similar delivery mechanisms
• Advances in minimally invasive surgical techniques reducing need for intravesical therapies
• Off-label use of systemic drugs

Financial and investment considerations

UroGen Pharma has reported limited revenues, with JELMYTO generating approximately $10-15 million in 2022. Cost structure includes manufacturing, R&D, marketing, and sales.

The company's valuation hinges on:

• Near-term revenue growth
• Successful market expansion
• Development of additional indications or formulations

Key financial metrics:

Metric	2022 Actual	2023 Estimate (Projected)
Revenue	~$15 million	~$30 million
R&D expenses	~$25 million	~$20 million
Net loss	~$80 million	~$70 million
Cash and equivalents	~$150 million	—

The company's cash runway extends into late 2024, assuming current expenditure levels.

What strategic considerations exist?

Investors should monitor:

• FDA post-marketing study timelines
• Market access developments
• Expansion into Europe and other regions
• New indications or formulation improvements

Given the niche market and early-stage commercialization, growth prospects depend heavily on clinical and market acceptance.

---

Key Takeaways

• JELMYTO is a niche, innovative treatment for LG UTUC, with limited but growing sales potential.
• Market size in the U.S. is approximately 2,500–3,000 cases annually, with revenues projected to reach $100–150 million by 2027.
• The commercial pathway faces challenges including payer coverage, physician adoption, and competitive advancements.
• Regulatory risks are minimal; however, post-marketing surveys are necessary for continued approval.
• The company’s financial health remains dependent on successful commercialization and market expansion.

---

FAQs

1. What is the primary FDA-approved indication for JELMYTO?
JELMYTO is approved for the treatment of low-grade upper urinary tract urothelial cancer (LG UTUC) in adults.

2. How large is the target population for JELMYTO in the U.S.?
Approximately 2,500 to 3,000 new cases of LG UTUC are diagnosed annually in the U.S.

3. What are the key barriers to market growth?
Barriers include limited patient awareness, payer reimbursement hurdles, and competition from surgical standards.

4. Are there any significant safety concerns associated with JELMYTO?
Long-term safety data are pending. No major safety concerns have emerged from clinical trials to date.

5. What are the prospects for international expansion?
Potential exists, especially in markets with similar regulatory frameworks. However, no formal approvals outside the U.S. have been announced.

---

References

[1] UroGen Pharma. (2022). JELMYTO prescribing information. Retrieved from https://www.jelmyto.com
[2] U.S. Food and Drug Administration. (2021). FDA approves JELMYTO for low-grade UTUC.
[3] MarketWatch. (2023). Nephro-urology drug market analysis and forecasts.
[4] IQVIA. (2022). Uro-Oncology Market Dynamics.